Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
TPTempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST)

NASDAQ Capital Market · Currency in USD
$0.51 ▼ -0.01 (-2.16%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.53 ▲ +0.02 (+3.70%)
After hours: Oct 23, 7:52 PM ET

Summary

Previous Close
$0.52
Open
$0.53
Day's Range
$0.51 – $0.53
52 Week Range
$0.50 – $11.13
Volume
52,222
Avg. Volume
196,579
Market Cap
$8.63M
Beta (5Y Monthly)
-1.71
PE Ratio (TTM)
--
EPS (TTM)
-$2.66
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Tempest Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
Matthew Angel

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.32
DateEst.Actual
Aug 13, 2026-$0.30-$0.34Miss
May 14, 2026-$0.28-$2.53Miss
Mar 31, 2026-$0.62-$0.62Beat
Nov 5, 2025-$3.27-$0.79Beat
Aug 11, 2025-$3.23-$2.07Beat
May 13, 2025-$3.71-$3.16Beat

Analyst view

Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on TPST and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.